Safety,Tolerability,and Pharmacokinetics Profiles of GB001 Recombinant Peptide Spray in Healthy Subjects

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 8, 2022

Primary Completion Date

November 18, 2022

Study Completion Date

May 29, 2026

Conditions

Healthy

Interventions

DRUG

GB001 recombinant peptide spray

administrated oral spray

DRUG

Placebo

administrated oral spray

Trial Locations (1)

The First Affiliated Hospital of Nanjing medical University, Nanjing

All Listed Sponsors

lead

Zhejiang Echon Biopharm Limited

INDUSTRY